Bis(N,N-dimethylhydroxamido)hydroxooxovanadate inhibition of protein tyrosine phosphatase activity in intact cells: Comparison with vanadate

Biochemical Pharmacology

Volumn 58, Issue 12, 1999, Pages 1859-1867

  Cuncic, Cary ^a   Desmarais, Sylvie ^a   Detich, Nancy ^a   Tracey, Alan S ^b   Gresser, Michael J ^a   Ramachandran, Chidambaram ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Dimethylhydroxamidohydroxooxovanadate; Glucose transport; Glycogen synthesis; Insulin action; Protein tyrosine phosphatase; Vanadate

Indexed keywords

BIS(N,N DIMETHYLHYDROXAMIDO)HYDROXOOXOVANADATE; DEOXYGLUCOSE; GLYCOGEN; INSULIN RECEPTOR; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; UNCLASSIFIED DRUG; VANADIC ACID;

ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CHO CELL; ENZYME INHIBITION; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

3T3 CELLS; ANIMALS; BIOLOGICAL TRANSPORT; CHO CELLS; CRICETINAE; ENZYME INHIBITORS; GLUCOSE; GLYCOGEN; HUMANS; JURKAT CELLS; MICE; PHOSPHOTYROSINE; PROTEIN-TYROSINE-PHOSPHATASE; RECEPTOR, INSULIN; VANADATES;

EID: 0032751619     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00284-1     Document Type: Article

References (44)

1. Hunter T. Protein kinases and phosphatases The yin and yang of protein phosphorylation and signaling . Cell. 80:1995;225-236.
2. Denu J.M., Dixon J.E. Protein tyrosine phosphatases Mechanisms of catalysis and regulation . Curr Opin Chem Biol. 2:1998;633-641.
3. Zhang Z.-Y. Protein-tyrosine phosphatases Biological function, structural characteristics and mechanism of catalysis . Crit Rev Biochem Mol Biol. 33:1998;1-52.
4. Neel B.G., Tonks N.K. Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol. 9:1997;193-204.
5. a of the active site cysteine and the function of the conserved histidine 402 . Biochemistry. 32:1993;9340-9345.
6. Liotta A.S., Kole H.K., Fales H.M., Roth J., Bernier M. A synthetic tris-sulfotyrosyl dodecapeptide analogue of the insulin receptor 1146-kinase domain inhibits tyrosine dephosphorylation of the insulin receptor in situ. J Biol Chem. 269:1994;22996-23001.
7. 2Pmp. Biochem Biophys Res Commun. 204:1994;129-134.
8. Zhang Z.Y., Maclean D., McNamara D.J., Sawyer T.K., Dixon J.E. Protein tyrosine phosphatase substrate specificity Size and phosphotyrosine positioning requirements in peptide substrates . Biochemistry. 33:1994;2285-2290.
9. Kole H.K., Akamatsu M., Ye B., Yan X., Barford D., Roller P.P., Burke T.R. Jr. Protein-tyrosine phosphatase inhibition by a peptide containing the phosphotyrosyl mimetic, L-O-malonyltyrosine. Biochem Biophys Res Commun. 209:1995;817-822.
10. Burke T.R. Jr, Ye B., Akamatsu M., Ford H. Jr, Yan X., Kole H., Wolf G., Shoelson S.E., Roller P.P. 4′-O-[2-(2-Fluoromalonyl)]-L-tyrosine A phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides . J Med Chem. 39:1996;1021-1027.
11. Burke T.R. Jr, Ye B., Yan X., Wang S., Jia Z., Chen L., Zhang Z.Y., Barford D. Small molecule interactions with protein-tyrosine phosphatase PTP1B and their use in inhibitor design. Biochemistry. 35:1996;15989-15996.
12. Huyer G., Kelly J., Moffat J., Zamboni R., Jia Z., Gresser M.J., Ramachandran C. Affinity selection from peptide libraries to determine substrate specificity of protein tyrosine phosphatases. Anal Biochem. 258:1998;19-30.
13. Desmarais S., Friesen R.W., Zamboni R., Ramachandran C. [Difluro(phosphono)methyl]phenylalanine-containing peptide inhibitors of protein tyrosine phosphatases. Biochem J. 337:1999;219-223.
14. Swarup G., Cohen S., Garbers D.L. Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochem Biophys Res Commun. 107:1982;1104-1109.
15. Denu J.M., Lohse D.L., Vijayalakshmi J., Saper M.A., Dixon J.E. Visualization of intermediate and transition-state structures in protein-tyrosine phosphatase catalysis. Proc Natl Acad Sci USA. 93:1996;2493-2498.
16. Huyer G., Liu S., Kelly J., Moffat J., Payette P., Kennedy B., Tsaprailis G., Gresser M.J., Ramachandran C. Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J Biol Chem. 272:1997;843-851.
17. Shechter Y. Insulin-mimetic effects of vanadate. Possible implications for future treatment of diabetes. Diabetes. 39:1990;1-5.
18. Elberg G., Li J., Shechter Y. Mechanisms of actions of vanadium in mediating the biological effects of insulin. Adv Environ Sci Technol. 31:1998;277-296.
19. 2 potentiates phosphorylation of novel putative substrates for the insulin receptor kinase in intact Fao cells. J Biol Chem. 264:1989;10126-10132.
20. Zippel R., Morello L., Brambilla R., Comoglio P.M., Alberghina L., Sturani E. Inhibition of phosphotyrosine phosphatases reveals candidate substrates of the PDGF receptor kinase. Eur J Cell Biol. 50:1989;428-434.
21. Trudel S., Downey G.P., Grinstein S., Paquet M.R. Activation of permeabilized HL60 cells by vanadate Evidence for divergent signalling pathways . Biochem J. 269:1990;127-131.
22. Grinstein S., Furuya W., Lu D.J., Mills G.B. Vanadate stimulates oxygen consumption and tyrosine phosphorylation in electropermeabilized human neutrophils. J Biol Chem. 265:1990;318-327.
23. Chao W., Liu H., Olson M.S. Effect of orthovanadate on tyrosine phosphorylation of p120 GTPase-activating protein rat liver macrophages (Kupffer cells). Biochem Biophys Res Commun. 191:1993;55-60.
24. Fantus I.G., Deragon G., Lai R., Tang S. Modulation of insulin action by vanadate Evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling . Mol Cell Biochem. 153:1995;103-112.
25. Pugazhenthi S., Tanha F., Dahl B., Khandelwal R.L. Inhibition of a Src homology 2 domain containing protein tyrosine phosphatase by vanadate in the primary culture of hepatocytes. Arch Biochem Biophys. 335:1996;273-282.
26. Krejsa C.M., Nadler S.G., Esselstyn J.M., Kavanagh T.J., Ledbetter J.A., Schieven G.L. Role of oxidative stress in the action of vanadium phosphotyrosine phosphatase inhibitors. Redox independent activation of NF-κB. J Biol Chem. 272:1997;11541-11549.
27. Paul P.C., Angus-Dunne S.J., Batchelor R.J., Einstein F.W.B., Tracey A.S. Reactions of vanadate with N,N-dimethylhydroxylamine Aqueous equilibria and the crystal structure of the uncharged oxygen bridged dimer of bis(N,N-dimethylhydroxamido)hydroxooxovanadate . Can J Chem. 75:1997;429-440.
28. Nxumalo F., Glover N.R., Tracey A.S. Kinetics and molecular modelling studies of the inhibition of protein tyrosine phosphatases by N,N-dimethylhydroxylamine complexes of vanadium(V). J Biol Inorg Chem. 3:1998;534-542.
29. Yoshimasa Y., Paul J.I., Whittaker J., Steiner D.F. Effects of amino acid replacements within the tetrabasic cleavage site on the processing of the human insulin receptor precursor expressed in Chinese hamster ovary cells. J Biol Chem. 265:1990;17230-17237.
30. Shepherd P.R., Nave B.T., Siddle K. Insulin stimulation of glycogen synthesis and glycogen synthase activity is blocked by wortmannin and rapamycin in 3T3-L1 adipocytes Evidence for the involvement of phosphoinositide 3-kinase and p70 ribosomal protein-S6 kinase . Biochem J. 305:1995;25-28.
31. Lawrence J.C., Roach P.J. New insights into the role and mechanism of glycogen synthase activation by insulin. Diabetes. 46:1997;541-547.
32. Mendz G.L. Catalytic effects of vanadium on phosphoryl transfer enzymes. Adv Environ Sci Technol. 30:1998;307-332.
33. Meyerovitch J., Farfel Z., Sack J., Shechter Y. Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action. J Biol Chem. 262:1987;6658-6662.
34. Brichard S.M., Pottier A.M., Henquin J.-C. Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rats. Endocrinology. 125:1989;2510-2516.
35. Brichard S.M., Bailey C.J., Henquin J.-C. Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate. Diabetes. 39:1990;1326-1332.
36. Meyerovitch J., Rothenberg P., Shechter Y., Bonner-Wei S., Kahn C.R. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J Clin Invest. 87:1991;1286-1294.
37. Brichard S.M., Ongemba L.N., Henquin J.-C. Oral vanadate decreases muscle insulin resistance in obese fa/fa rats. Diabetologia. 35:1992;522-527.
38. Goldfine A.B., Simonson D.C., Folli F., Patti M.-E., Kahn C.R. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. J Clin Endocrinol Metab. 80:1995;3311-3320.
39. Cohen N., Halberstam M., Shlimovich P., Chang C.J., Shamoon H., Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 95:1995;2501-2509.
40. Gresser MJ and Tracey AS, Vanadates as phosphate analogs in biochemistry. In: Vanadium in Biological Systems (Ed. Chasteen ND), pp. 63-79. Kluwer Academic Publishers, Dordrecht, The Netherlands, 1990.
41. Poucheret P., Verma S., Grynpas M.D., McNeill J.H. Vanadium and diabetes. Mol Cell Biochem. 188:1998;73-80.
42. Crans D.C. Peroxo, hydroxylamido and Acac derived vanadium complexes Chemistry, biochemistry, and insulin-mimetic action of selected vanadium compounds . ACS Symp Ser. 711:1998;82-103.
43. Pfefferkorn L.C., Swink S.L. Intracluster restriction of Fc receptor γ-chain tyrosine phosphorylation subverted by a protein-tyrosine phosphatase inhibitor. J Biol Chem. 271:1996;11099-11105.
44. Nxumalo F., Tracey A.S. Reactions of vanadium(V) complexes of N,N-dimethylhydroxylamine with sulfur-containing ligands Implications for protein tyrosine phosphatase inhibition . J Biol Inorg Chem. 3:1998;527-533.